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Abstract The hepatitis C virus (HCV) protease genes (NS2/3
and NS3) were expressed in yeast with their natural substrates
fused to a ligand-dependent transcriptional activator, the retinoic
acid receptor (RARL). RARL can activate transcription in yeast
cells in response to retinoic acids. We hypothesized that cis-
cleavage at the NS2^3 or NS3^4A junctions by the appropriate
HCV proteases would release RARL, thereby activating
transcription of a reporter gene. Our results from Western blot
analyses and reporter gene activation indicate that the wild-type
NS2/3 and NS3 enzymes are catalytically active in yeast cells,
whereas mutations in the catalytic domain of NS2(C993V) and
NS3(S1165A) lead to inactive enzymes. We conclude that HCV
NS2/3 and NS3 protease activities can be reconstituted in
yeast. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Hepatitis C virus (HCV), which belongs to the Flaviviridae
family, is a positive-sense single-stranded RNA virus with a
genome of 9.6 kb in length. The viral proteins are produced
from a single long open reading frame encoding a polyprotein
of 3010 amino acid residues in the order of NH2-C-E1-E2-p7-
NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH [1,2]. Polypro-
tein processing is mediated by host signal peptidases as well
as by HCV encoded proteases, NS2/3 and NS3 [3,4]. The
enzymatic activity of the NS2/3 HCV protease requires amino
acid sequences located in the C-terminal half of the NS2 gene
linked to the N-terminal one third of the NS3 gene (aa 907^
1207) (unpublished observation) and is responsible for the
cleavage at the NS2/NS3 junction. Cleavage at the NS2/NS3
junction is a rapid zinc-dependent intramolecular event. Pre-
viously, His-952 and Cys-993 have been described as essential
residues for enzymatic activity since mutation of either one of
these amino acids inactivates the enzyme [5,6]. The amino-
terminal domain of NS3 also encodes a serine protease, which
cleaves at the NS3/4A junction in cis followed by the cleavage
at the NS4A/B, NS4B/5A and NS5A/B sites in trans [7,8].
E⁄cient proteolytic activity of NS3 requires the NS4A protein
as a cofactor [9,10]. Since viral proteases are indispensable for
viral replication, they are attractive targets for developing
antiviral therapies. Indeed, many academic and industrial lab-
oratories have developed in vitro assays for the identi¢cation
of speci¢c protease inhibitors against NS3 and to a lesser
extent, NS2/3 protease [11,12]. Saccharomyces cerevisiae has
been exploited as a novel host to study mammalian transcrip-
tion factors [13^15] as well as to determine substrate speci¢c-
ity of hepatitis C virus NS3 protease [16]. In this report, we
further employed this yeast expression system to examine the
feasibility of studying HCV protease activity in yeast cells.
Our results indicate that this genetic system is a useful tool
to study viral protease activity in vivo, thus allowing the de-
velopment of a screening method to identify speci¢c viral
protease inhibitors.
2. Materials and methods
2.1. Cells
The S. cerevisiae strain (BJ2168) containing the YEpcRARL and
YEpA plasmids has been described previously [14,15]. Growth and
transformation of yeast cells were performed according to standard
procedures [17]. Double transformant yeast strains were grown in
synthetic dropout medium to maintain expression plasmids.
2.2. Plasmids
YEpcRARL is a copper inducible expression plasmid for the human
retinoic acid receptor-L fused at its N-terminus to the ubiquitin gene
under control of the CUP1 promoter. DNA sequences encompassing
the HCV NS2/3 protease domain, composed of full-length NS2 pro-
tein linked to the N-terminal 181 amino acids of NS3 (aa 810^1207 of
the HCV polyprotein), were constructed by standard PCR ampli¢ca-
tion, using cDNA of HCV H strain as a template [3]. Sequences
composed of full-length NS3 protease linked to NS4A and the ¢rst
19 amino acids of NS4B (aa 1027^1730) were constructed similarly.
The resulting PCR fragments were cloned in frame by blunt-end liga-
tion between the ubiquitin and the RARL gene at the EagI site of
YEpcRARL [15]. The NS2/3(C993V) and the NS3(S1165A) mutants
were obtained using the QuickChange1 site-directed mutagenesis kit
(Stratagene). The resulting constructs, YEpcNS2/3-RARL, YEpcNS2/
3-RARL(mut), YEpcNS3/4AB19-RARL, and YEpcNS3/4AB19-RARL-
(mut) were sequenced to con¢rm the integrity of the genes. When
expressed in yeast, the 76 amino acid ubiquitin fragment will be
cleaved o¡ the fused protein by the endogenous ubiquitinase in yeast
producing the NS2/3-RARL and NS3/4AB19-RARL proteins. The
yeast reporter plasmid YEpA containing the lac-Z gene under the
control of the CYC1 promoter and the ApoAI site A enhancer
(GACTGAACCCTTGACCCCTGCCC) has been described else-
where [14,15].
2.3. Western blot analysis
Yeast cell lysates were prepared and subjected to Western blot
analyses as described previously [14,15]. Rabbit polyclonal antibody
C-19 raised against human RARL (Santa Cruz Biotechnology) was
used to probe the blot. HRP-conjugated anti-rabbit antibody (Amer-
sham Pharmacia Biotech) was used as secondary antibody and the
protein was detected using the ECL1 detection reagents (Amersham
Pharmacia Biotech).
2.4. Transcription assay
Double transformant yeast strains carrying the reporter plasmid
YEpA and one of the following expression constructs: YEpcRARL,
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YEpcNS2/3-RARL, YEpcNS2/3-RARL(mut), YEpcNS3/4AB19-RARL
or YEpcNS3/4AB19-RARL(mut), were grown in synthetic dropout
medium in the absence or presence of 100 WM cupric sulfate and
100 nM all-trans retinoic acid (Sigma). When cell density reached
late log phase, yeast cells were assayed for L-galactosidase induction
as described previously [14,15].
2.5. Indirect immuno£uorescence
An overnight yeast culture (OD = 1.0 at 600 nm) was ¢xed for 1 h
with 4% formaldehyde. The cells were then pelleted, washed once with
potassium phosphate (0.1 M, pH 7.5) and resuspended in the same
bu¡er containing zymolyase (50 Wg/ml) (Invitrogen) for 20 min at
30‡C. The cells were washed twice with phosphate bu¡er before and
after a 30 s treatment with 1% Triton X-100. The permeabilized cell
suspension (50 Wl) was spotted onto polylysine coated slides for 5 min
and subsequently washed twice with PBS and overlayed with 4% BSA
for 30 min at room temperature (RT) in a humid chamber. A rabbit
polyclonal IgG anti-RARL (Santa Cruz Biotechnology) was used as a
primary antibody. After 1 h incubation at RT, the slides were washed
three times, 5 min each with PBS and incubated with a donkey anti-
rabbit (FabP)2 FITC-conjugated antibody (Jackson Laboratories) for
1 h at RT. After three washes with PBS, the slides were overlayed
with DAPI solution (1 Wg/ml) (Sigma) for 1 min and mounted using
the Prolong antifade (Molecular Probes).
3. Results and discussion
3.1. NS3 protease activity in yeast
The concept of reconstituting HCV NS3 protease activity is
illustrated schematically in Fig. 1A. Cis-cleavage between NS3
and NS4A at aa 1657 will generate two cleaved products, i.e.
NS3 and NS4AB19-RARL. The interaction of NS4A with the
N-terminal amino acids of NS3 will promote cleavage of
NS4A from NS4B, resulting in the ¢nal chimeric receptor,
NS4B19-RARL. In contrast, the mutant chimera will be ex-
pressed as an uncleaved product (NS3^4AB19-RARL). Upon
expression of the wild-type NS3/4AB19-RARL polyprotein in
yeast, the NS3 protease would produce the following inter-
mediates: NS4AB19-RARL (63 kDa), NS4B19-RARL (57
kDa) as well as the uncleaved form, NS3/4AB19-RARL (133
kDa). Indeed, all these polyproteins were detected by Western
blot at the expected size using a polyclonal antibody against
RARL as shown in Fig. 1B. In contrast, when the protease
activity of NS3 was abolished by substitution of the serine at
position 1165 by an alanine (NS3(S1165A)), only the un-
cleaved form, NS3/4AB19-RARL (133 kDa) was observed by
Western blot. This observation further supports the notion
that NS3 is a serine protease [5,12]. However, a speci¢c serine
protease inhibitor for HCV NS3 protease is not available
commercially to validate this yeast genetic system. To demon-
strate the size of NS4AB19-RARL intermediate, a construct
YEpcNS4AB19-RARL expressing this protein was used to
transform yeast cells. As expected, the polyprotein has the
predicted size of 63 kDa (Fig. 1B). In some cases, low level
of protein expression was detected under non-induced condi-
tion (in the absence of cupric sulfate), this is due to the leaky
metallothionein (CUP1) promoter. The yeast strain carrying
the expression construct, YEpcNS3/4AB19-RARL, and the re-
porter plasmid, YEpA, exhibited a ligand-dependent transac-
tivation, which was similar to that observed for RARL (Fig.
1C). However, yeast strains harboring the mutant construct
YEpcNS3/4AB19-RARL(mut) or the YEpcNS4AB19-RARL
construct exhibited little or no reporter gene activation (Fig.
1C). These data clearly indicate that NS4B19-RARL is the
only intermediate that can function e⁄ciently as a transcrip-
tional activator in yeast and support the notion that the NS3/
4AB19-RARL polyprotein must undergo two cleavage reac-
tions by the NS3 to produce NS4B19-RARL. The fact that
NS4AB19-RARL fusion is not transcriptionally active suggests
that either the 54 residues of NS4A a¡ect the conformation of
the fusion protein, which interferes with the ability of RARL
to bind to DNA or ligand, or the highly hydrophobic moiety
of NS4A directs the fusion protein to yeast membranes, there-
by preventing translocation of the protein to the nucleus.
The indirect immuno£uorescence study indicated that
RARL from both active and inactive NS3 protease constructs
were mostly cytoplasmic in yeast cells in the absence of reti-
noic acid (Fig. 2C,E). However, in the presence of ligand,
RARL from the inactive NS3 protease construct still remained
cytoplasmic (Fig. 2F). Possible reasons include: (1) the size of
the uncleaved NS3/4AB19-RARL polyprotein was too big to
translocate into the nucleus, (2) the ligand binding domain at
the C-terminus of RARL was masked by the large N-terminal
domain of NS3, or (3) the hydrophobic NS4A sequences pre-
vented translocation. In contrast, cleavage of the polyprotein
by the active form of NS3 led to a RARL exhibiting both
cytoplasmic and nuclear localization in the presence of ligand
(Fig. 2D). The cytoplasmic form of the RARL is most likely
the uncleaved NS3/4AB19-RARL and/or the partially cleaved
NS4AB19-RARL, whereas the nuclear form is the NS4B19-
RARL. Nuclear localization of the NS4B19-RARL protein
would correlate directly with the transcriptional activation
of the lac-Z gene (Fig. 1C).
3.2. NS2/3 protease activity in yeast
The concept of reconstituting HCV NS2/3 protease in yeast
is based on the assumption that the N-terminal hydrophobic
domain of NS2 is cotranslationally anchored in the endoplas-
mic reticulum (ER) membranes (Fig. 3A, bottom). Thus, the
chimeric enzyme/substrate will be anchored to the cytoplasmic
surface of the ER in the absence of autocatalytic protease
activity (Fig. 3A). Autocleavage between aa 1026 and 1027
will release the chimeric receptor (NS3-RARL), which func-
tions as a ligand-activated transcription factor leading to re-
porter gene induction. In contrast, the mutant chimera, which
has an active site point mutation (C993V), will not exhibit
autocleavage. The uncleaved chimeric protein should be re-
tained on cytoplasmic surface of the ER membrane and there-
fore cannot function as a ligand-activated transcription factor.
In order to demonstrate the speci¢c cleavage between NS2
and NS3 by the NS2/3 protease in this system, a construct
expressing the wild-type NS2/3-RARL fusion protein was
used to transform yeast cells. Yeast cells carrying the expres-
sion plasmid, YEpcNS2/3-RARL, revealed two distinct pro-
tein bands that correspond to the predicted size of the un-
cleaved chimera (97 kDa) (top arrow) and the cleaved
product, NS3-RARL (74 kDa) (middle arrow). In contrast,
yeast cells harboring the mutant construct, YEpcNS2/3-
RARL(mut), resulted only in an uncleaved product (97 kDa
protein) (Fig. 3B). Under non-induced condition, low levels of
protein were detected for RARL (bottom arrow), uncleaved
wild-type NS2/3-RARL and cleaved NS3-RARL due to the
leaky metallothionein promoter (CUP1). These observations
clearly indicate that NS2^NS3 cis-cleavage can occur in yeast
cells with an e⁄ciency of cleavage of about 40^50% under the
conditions used in the present study, whereas the mutant chi-
mera cannot undergo self cleavage. We have consistently ob-
served that the expression level of the NS2/3-RARL mutant
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protein is much lower than that of the wild-type. NS2 is a
highly hydrophobic protein with four putative transmembrane
domains. It has been shown that NS2 protein is anchored to
the cytoplasmic surface of the endoplasmic reticulum (ER)
when expressed in mammalian cells [18]. Thus, it is most likely
that the uncleaved NS2/3-RARL mutant protein is cotransla-
tionally anchored to the ER membrane through the NS2 pro-
tein. It is possible that the association of the NS2/3-RARL
mutant polyprotein with the ER membrane has an ‘inhibitory
e¡ect’ on the synthesis and/or the accumulation of these chi-
meras in yeast cells. In fact, we were not able to detect the
mutant chimera by indirect immuno£uorescence (data not
shown). In contrast, the expression level of the wild-type
NS2/3-RARL polyprotein was comparable to that of RARL
based on Western blot analyses. Yeast transformants harbor-
ing the plasmids YEpcRARL or YEpcNS2/3-RARL exhibited
ligand-dependent transcriptional activation (Fig. 3C). We
have observed that the yeast strain carrying the plasmid,
YEpcNS2/3-RARL(mut), was unable to activate transcription
when yeast cells were incubated with both retinoic acid and
cupric sulfate (unpublished observations). A direct compari-
son in transcriptional activation between the wild-type and the
Fig. 1. A: Reconstitution of HCV NS3 protease activity in yeast. For the wild-type chimeric construct (YEpcNS3/4AB19-RARL), the entire
NS3 (aa 1027^1657), NS4A (aa 1658^1711) and the N-terminal 19 aa of NS4B (aa 1712^1730) were inserted in frame between the ubiquitin
gene (UB) and the RARL. The mutated version (YEpcNS3/4AB19-RARL(mut)) of this chimeric construct has a point mutation (S1165A) (top),
which will disrupt the cis- and trans-cleavage activity of NS3. The construct YEpcRARL was used as a control. Each of these expression con-
structs was used to transform yeast cells carrying the reporter plasmid, which contains two copies of a speci¢c enhancer, site A (GACT-
GAACCCTTGACCCCTGCCC) upstream of the CYC1 promoter (bottom). B: Western blot analysis of NS3/4AB19-RARL. Yeast cell lysates
were prepared from yeast strains expressing RARL, NS3/4AB19-RARL, NS3/4AB19-RARL(mut), or NS4AB19-RARL under non-induced (3) or
induced (+) conditions as described in Section 2. Equal volume of cell lysate was electrophoresed on 10% SDS^PAGE. Molecular weight stan-
dards are indicated in kDa. C: Ligand-dependent transcriptional activation of NS3/4AB19-RARL in yeast. Double transformant yeast strains
carrying the reporter plasmid and the expression constructs for RARL, NS3/4AB19-RARL, NS3/4AB19-RARL(mut), or NS4AB19-RARL were
grown in synthetic dropout medium containing 100 nM all-trans retinoic acid in the absence (empty bar) or presence (hatched bar) of 100 Wm
cupric sulfate. After overnight incubation at 30‡C, cells were harvested and analyzed for L-gal activity as described in Section 2. The results are
the average of two separate experiments.
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Fig. 2. Localization of the RARL protein in yeast cells by indirect immuno£uorescence. Yeast transformed with YEpcNS2/3-RARL (A, B),
YEpcNS3/4AB19-RARL (C, D) and YEpcNS3/4AB19-RARL(mut) (E, F) were probed with a rabbit polyclonal antibody raised against RARL.
DNA staining using DAPI reagent is shown in panels A1, B1, C1, D1, E1 and F1. Speci¢c RARL expressing cells are shown in panels A2, B2,
C2, D2, E2 and F2. Cells of interest are indicated by an arrow. A, C and E: Without retinoic acid. B, D and F; With retinoic acid.
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mutant chimera is not feasible due to the dramatic di¡erence
in the level of protein expression. The lack of activity by the
mutant NS2/3-RARL may simply be due to either the low
level of protein synthesis or retention of the mutant protein
at the ER membrane. If the latter is the case, then this would
predict that the conversion of uncleaved NS2/3-RARL (97
kDa) to the cleaved products NS2+NS3-RARL is required
for reporter gene induction in yeast cells.
Indirect immuno£uorescence indicated that RARL from
both uncleaved and cleaved NS2/3-RARL polyprotein were
localized in the cytoplasm of the cells in the absence of reti-
noic acid (Fig. 2A). In contrast, RARL were detected mainly
in the nucleus when the cells were incubated with retinoic acid
(Fig. 2B). It is not clear in the present study whether nuclear
localization of RARL represents both cleaved (NS3-RARL)
and uncleaved (NS2/3-RARL) chimeras. Nevertheless, these
observations are in agreement with the mechanism of steroid
hormone action [19,20].
3.3. NS2/3 and NS3 proteases are attractive antiviral targets
for small molecule inhibitors
HCV non-structural protein processing is achieved by NS2/
3 and NS3 proteases, which are essential for viral replication.
Therefore, these proteases are good targets for antiviral ther-
Fig. 3. A: Reconstitution of HCV NS2/3 protease activity in yeast cells. The three ubiquitin (UB) fusion yeast expression plasmids are shown
in top. Each of these expression constructs was used to transform yeast cells carrying the reporter plasmid, which contains two copies of a spe-
ci¢c enhancer, site A (GACTGAACCCTTGACCCCTGCCC) upstream of the CYC1 promoter (bottom). The resulting double transformant
yeast strain was analyzed for reporter gene (lac-Z) induction as well as protein expression. B: Western blot analysis of NS2/3-RARL. Yeast cell
lysates were prepared from yeast strains expressing RARL, wild-type NS2/3-RARL or mutant NS2/3-RARL(mut) under non-induced (3) or in-
duced (+) conditions as described in Section 2. Equal volume of cell lysate was electrophoresed on 10% SDS^PAGE. The arrows (from top to
bottom) indicate the size of uncleaved NS2/3-RARL, NS3-RARL and RARL respectively. Non-speci¢c immunoreactive bands were indicated
by asterisk. Molecular weight standards are indicated in kDa. C: Ligand-dependent transcriptional activation of NS2/3-RARL in yeast. Double
transformant yeast strains carrying the reporter plasmid and the expression constructs for RARL or wild-type NS2/3-RARL were grown in syn-
thetic dropout medium containing 100 nM all-trans retinoic acid in the absence (empty bar) or presence (hatched bar) of 100 Wm cupric sulfate.
After overnight incubation at 30‡C, cells were harvested and analyzed for L-gal activity as described in Section 2. The results are the average
of two separate experiments.
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apy. In the present study, we were able to reconstitute NS2/3
protease activity in yeast cells, which can be exploited as an
e⁄cient screening tool to identify novel small molecule inhib-
itors. This can be achieved by screening compounds that can
inhibit the reporter gene induction (lac-Z) or the conversion of
uncleaved NS2/3-RARL polyprotein to a cleaved NS3-RARL
product as detected by Western blots. Likewise, the same
screening strategy can be applied to NS3 protease. In sum-
mary, we have exploited the yeast genetic system to reconsti-
tute HCV protease activities, which can be used to develop a
screening assay to identify small molecule inhibitors for both
HCV proteases. Furthermore, this system will also be useful
for structure^function analyses of these proteases in cells.
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